-

Shareholder Alert: Robbins LLP Reminds Investors that Evolus, Inc. (EOLS) is Being Sued for Misleading Shareholders

SAN DIEGO & NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP reminds investors that Evolus, Inc. (NASDAQ: EOLS) is being sued for alleged violations of the Securities Exchange Act of 1934 between February 1, 2019 and July 6, 2020. Evolus, Inc. provides medical aesthetic products for physicians and their patients in the United States. Evolus' sole product is Jeuveau™ competes with Botox®.

If you suffered a loss due to Evolus, Inc.'s misconduct, click here.

Evolus, Inc. (EOLS) Accused of Misappropriating Trade Secrets

According to the complaint, beginning in February 2019, Evolus began a campaign in which it promoted Jeuveau™ as a proprietary formulation of the botulinum toxic type A complex, purportedly developed by a Korean bioengineering company through years of clinical research. On July 6, 2020, the investing public learned the truth when the U.S. International Trade Commission ("ITC") issued its Initial Final Determination in a case brought by Allergan and Medytox against Evolus, which claimed that Evolus stole trade secrets to develop Jeuveau. The ITC Judge determined that Evolus and its South Korean partner firm misappropriated the botulinum toxin and the manufacturing process that led to its development and manufacture. As a result, the ITC Judge recommended a ten-year long ban on Evolus' ability to import and sell Jeuveau in the United States. On this news, Evolus' stock dropped 37% in two days to close at $3.35 on July 8, 2020 and has yet to recover.

If you purchased Evolus, Inc. (EOLS) securities between February 1, 2019 and July 6, 2020, you have until December 15, 2020, to ask the court to appoint you lead plaintiff for the class.

Contact us to learn more:
Lauren Levi
(800) 350-6003
llevi@robbinsllp.com
Shareholder Information Form

Robbins LLP is a nationally recognized leader in shareholder rights law. To be notified if a class action against Evolus, Inc. settles or to receive free alerts about companies engaged in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Lauren Levi
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
llevi@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

More News From Robbins LLP

Investor Alert: Robbins LLP Informs Investors of the Corcept Therapeutics Inc. Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Corcept Therapeutics Incorporation (NASDAQ: CORT) common stock between October 31, 2024 and December 30, 2025. Corcept is a pharmaceutical company focused on the development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol. For more information, submi...

ARDT Class Action Reminder: Stockholders Who Lost Money Investing in Ardent Health, Inc. Should Contact Robbins LLP for Information About Recovering Their Losses

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Ardent Health, Inc. (NYSE: ARDT) securities between July 18, 2025 and November 12, 2025. Ardent Health and its affiliates operate acute care hospitals and other healthcare facilities. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. What are the allegations? Robbins LLP is Investigating...

Investor Notice: Shareholder Rights Law Firm Robbins LLP Informs Investors of the NuScale Power Corporation Securities Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired NuScale Power Corporation (NYSE: SMR) Class A shares between May 13, 2025 and November 6, 2025. NuScale is a nuclear technology company focused on scalable, modular reactors. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The Allegations: Robbins LLP is Investigating Allegations that...
Back to Newsroom